

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: August 31, 2005

ATTY DOCKET NO.
2005_0859ASERIAL NO.
10/537,313APPLICANT
Michiaki NAGASAWA et al.FILING DATE
June 2, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AE						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
NR	AJ	2000-224992	08/2000	JP			
NR	AK	11-302190	11/1999	JP			
NR	AL	01/40226	06/2001	WO			
NR	AM	01/24781	04/2001	WO			
NR	AN	00/09127	02/2000	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

NR	AO	"Inhibitory Effect of Ibudilast (KC-404) on Cyclic Nucleotide Phosphodiesterases", Seiko Murashima: Mie Prefectural College of Nursing, et al., (Jpn Pharmacol Ther) Vol. 26, No. 1 (1998), 41-45.
NR	AP	"Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone" John E. Souness et al., Br.J. Pharmacol. (1994) 111, 1081-1088.
NR	AQ	"Ibudilast Modulates Platelet-Endothelium Interaction Mainly Through Cyclic GMP-Dependent Mechanism", Journal of Cardiovascular Pharmacology 36(1) pp 65-70 (2000), KISHI, Y. et al.
NR	AR	"Drug for improvement of Brain Circulation and Metabolism, and How to Use It", Hirotohi Kasahara, et al., Clinica, 1990, 17 (5), pages 256-262.

EXAMINER

DATE CONSIDERED

08-24-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.